Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas

Chopinet, Sophie; Cauchy, François; Hobeika, Christian; Beaufrère, Aurélie; Poté, Nicolas; Farges, Olivier; Dokmak, Safi; Bouattour, Mohamed; Ronot, Maxime; Vilgrain, Valérie; Soubrane, Olivier

doi:10.1016/j.jhepr.2021.100326

Cited by 8 publications

(10 citation statements)

References 28 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study of malignancy in HCA cases reported a surprisingly high frequency of malignant transformation of IHCA without b-catenin mutation. 66 However, these findings could not be replicated by another recent study. 67…”

Section: H C Amentioning

confidence: 73%

“…A subset of IHCAs contain an additional cadherin‐associated protein β1 gene ( CTNNB1 ) mutation and represent another HCA subtype, β‐catenin‐mutated IHCA (b‐IHCA) (see below), which may progress to HCC. A recent study of malignancy in HCA cases reported a surprisingly high frequency of malignant transformation of IHCA without β‐catenin mutation 66 . However, these findings could not be replicated by another recent study 67 …”

Section: Hca Classificationmentioning

confidence: 93%

“…Another unsolved issue is the prognosis of HCA‐derived HCCs, which are mostly well differentiated 67 . A recent study showed better long‐term survival for these patients than for those with non‐HCA‐derived HCC in non‐cirrhotic livers 66 . According to the few studies that have been able to follow patients with an exon 3 CTNNB1 ‐mutated HCA that was incompletely resected, malignant transformation seems to take at least 10 years 85 …”

Section: Hca Complicationsmentioning

confidence: 99%

See 2 more Smart Citations

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

View full text Add to dashboard Cite

Hepatocellular adenoma: what we know, what we do not know, and why it mattersIn the last two decades there has been significant progress in research on and diagnosis of hepatocellular adenoma (HCA), resulting in the establishment of a molecular and immunohistological HCA classification. This review aims to fine-tune the current expertise in order to enhance the histopathological diagnostic possibilities, by refining issues that are already known, addressing diagnostic difficulties, and identifying still unknown aspects of HCA. We discuss novel methods to identify HCA subtypes, in particular the sonic hedgehog HCAs and the interpretation of glutamine synthetase patterns for the recognition of b-cateninmutated HCAs. The major complications of HCAs, i.e. bleeding and malignant transformation, are considered, including the dilemmas of atypical and borderline lesions. HCAs in different clinical and geographical settings, e.g. pregnancy, cirrhosis and non-western countries, are also discussed. The natural history of the different HCA subtypes in relation to age, sex and risk factors is a feature that is still insufficiently investigated. This is also true for the risks of clinical bleeding and malignant transformation in association with HCA subtypes. As HCA is a relatively rare tumour, a multicentre and multidisciplinary approach across geographical boundaries will be the appropriate method to establish prospective programmes with which to identify, classify and manage HCAs, focusing on several aspects, e.g. aetiology, underlying liver disease, complications, regression, and growth. Updating what we know and identifying and addressing what we do not know matters for optimal patient management.

show abstract

Section: H C Amentioning

confidence: 73%

Section: Hca Classificationmentioning

confidence: 93%

Section: Hca Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

View full text Add to dashboard Cite

show abstract

“…on long-term outcomes following resection of hepatocellular adenoma with malignant transformation (MT-HCA). 1 …”

mentioning

confidence: 99%

Malignant transformation of hepatocellular adenoma

et al. 2022

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…We are pleased to address the issues they raised regarding our study, which concerns a matched case-control study comparing the long-term outcome after liver resection for HCA with malignant transformation (MT-HCA) to hepatocellular carcinoma (HCC) developed on normal liver-parenchyma. 2 …”

mentioning

confidence: 99%